Curium Pharma, a developer, manufacturer, and distributor of nuclear medicine, has acquired Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a nuclear medicine player headquartered in Istanbul, Turkey.

The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval).

Monrol complements Curium’s R&D capabilities as it continues to expand its portfolio and pipeline of theranostic products. Curium intends to deploy Monrol’s Ga-68 generator globally in the future, pending regulatory approvals.

In addition, Monrol’s PET & SPECT complementary geographic footprint further expands Curium’s offering. The completion of the deal expands Curium’s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol-owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium’s vertically integrated production and distribution capabilities.

Chaitanya Tatineni, Curium’s CEO of International Markets, commented: “We are delighted to welcome close to 400 highly-skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.”

Aydin Kucuk, General Manager at Monrol, added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world-class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium’s global footprint, product portfolio, and track record of innovation.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.